title: Vitreous and plasma VEGF levels as predictive factors in the progression of proliferative diabetic retinopathy after vitrectomy.
abstract: OBJECTIVE
  To investigate the vitreous and plasma levels of vascular endothelial growth factor (VEGF) in patients with proliferative diabetic retinopathy (PDR) and to determine whether they predict a disease prognosis after primary vitrectomy.
  
  
  METHODS
  Fifty patients (50 eyes) with PDR who underwent pars plana vitrectomy (PPV) and 56 healthy controls (56 eyes) were enrolled in this retrospective study. Clinical data were collected and analyzed. Vitreous and plasma VEGF concentrations were measured using enzyme-linked immunosorbent assays. VEGF levels and clinical data were compared and analyzed to see if they provide a prognosis of PDR progression after primary vitrectomy at more than 6 months follow-up. Correlation of VEGF concentrations between vitreous fluid and plasma was analyzed.
  
  
  RESULTS
  The average BCVA was significantly improved after surgery (P<0.001). Vitreous and plasma VEGF levels were significantly elevated in PDR patients than those in healthy controls (P vitreous<0.001; P plasma<0.001). Both vitreous and plasma VEGF levels were significantly higher in PDR progression group than in stable group (P vitreous < 0.001; P plasma = 0.004). Multivariate logistic regression analyses showed that the increased vitreous VEGF level was associated with the progression of PDR after primary PPV (OR = 1.539; P = 0.036). Vitreous VEGF level was positively associated with plasma VEGF level in PDR patients (P<0.001).
  
  
  CONCLUSIONS
  The increased VEGF level in vitreous fluid may be identified as a significant predictive factor for the outcome of vitrectomy in patients with PDR.
authors.affiliation: Department of Ophthalmology, Tianjin Medical University General Hospital, Tianjin, China.
authors.forename: Jiaxing
authors.initials: J
authors.lastname: Wang
authors.affiliation: Department of Ophthalmology, Tianjin Medical University General Hospital, Tianjin, China.
authors.forename: Song
authors.initials: S
authors.lastname: Chen
authors.affiliation: Department of Ophthalmology, Tianjin Medical University General Hospital, Tianjin, China.
authors.forename: Feng
authors.initials: F
authors.lastname: Jiang
authors.affiliation: Department of Ophthalmology, Tianjin Medical University General Hospital, Tianjin, China.
authors.forename: Caiyun
authors.initials: C
authors.lastname: You
authors.affiliation: Department of Ophthalmology, Tianjin Medical University General Hospital, Tianjin, China.
authors.forename: Chunjie
authors.initials: C
authors.lastname: Mao
authors.affiliation: Department of Ophthalmology, Tianjin Medical University General Hospital, Tianjin, China.
authors.forename: Jinguo
authors.initials: J
authors.lastname: Yu
authors.affiliation: Department of Ophthalmology, Tianjin Medical University General Hospital, Tianjin, China.
authors.forename: Jindong
authors.initials: J
authors.lastname: Han
authors.affiliation: Department of Ophthalmology, Tianjin Medical University General Hospital, Tianjin, China.
authors.forename: Zhuhong
authors.initials: Z
authors.lastname: Zhang
authors.affiliation: Department of Ophthalmology, Tianjin Medical University General Hospital, Tianjin, China.
authors.forename: Hua
authors.initials: H
authors.lastname: Yan
mesh_terms: D000328:Adult; D000368:Aged; D003930:Diabetic Retinopathy / Q000097:blood* / Q000473:pathology; D018450:Disease Progression; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D042461:Vascular Endothelial Growth Factor A / Q000097:blood*; D014821:Vitrectomy / Q000009:adverse effects*; D014822:Vitreous Body / Q000378:metabolism
chemical_list: C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A